Current status of research concerning neuroinflammation schizophrenia

doi:10.3969/j.issn.1006-7795.2019.02.010

Abstract

Abstract: Schizophrenia is a common mental disorder, the mechanism of which remains unknown at present. Many hypotheses have been put forward. As early as the 1980s, three were the clinical studies showing that schizophrenia activated the inflammatory response and the immune system disorders in the peripheral nervous system and the brain. In recent years, psychiatric drugs and anti-inflammatory drugs are used in combination to improve the symptoms in schizophrenic patients, suggesting that nerve inflammation played a role in the onset of schizophrenia. The neuroinflammation effects on schizophrenia are reviewed in this article.

Key words: schizophrenia, neuroinflammation, cytokines

CLC Number:

R749

Ma Chao, Jia Hongxiao. Current status of research concerning neuroinflammation schizophrenia[J]. Journal of Capital Medical University, 2019, 40(2): 205-208.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.02.010

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I2/205

References

[1] Huang Y Q, Wang Y, Wang H, et al. Prevalence of mental disorders in China:a cross-sectional epidemiological study[J]. Lancet Psychiatry, 2019,6(3):211-224.
[2] Gilmour G, Dix S, Fellini L, et al. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis[J]. Neuropharmacology, 2012, 62(3):1401-1412.
[3] Mosser C A, Baptista S, Arnoux I, et al. Microglia in CNS development:shaping the brain for the future[J]. Progr Neurobiol, 2017, 149-150:1-20.
[4] Busse M, Bielau H, Müller, et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia:further evidence for disease course-related immune alterations?[J]. Brain Behav Immun, 2012, 26(8):1273-1279.
[5] Mallya A P, Wang H D, Lee H N R, et al. Microglial pruning of synapses in the prefrontal cortex during adolescence[J]. Cereb Cortex, 2019,29(4):1634-1643.
[6] Fuller S, Steele M, Münch G, et al. Activated astroglia during chronic inflammation in alzheimer's disease-do they neglect their neurosupportive roles?[J]. Mutat Res, 2010, 690(1-2):40-49.
[7] Uranova N A, Vikhreva O V, Rachmanova V I, et al. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia:a postmortem morphometric study[J]. Schizophr Res Treatment, 2011, 2011:325789.
[8] Tsai S J. Effects of, interleukin-1beta, polymorphisms on brain function and behavior in healthy and psychiatric disease conditions[J]. Cytokine Growth Factor Rev, 2017,37:89-97.
[9] Yirmiya R, Winocur G, Goshen I. Brain interleukin-1 is involved in spatial memory and passive avoidance conditioning[J]. Neurobiol Learn Mem, 2002, 78(2):379-389.
[10] Ghafelehbashi H, Pathleran Kakhki M, Kular L, et al. Decreased expression of IFNG-AS1, IFNG and IL-1B inflammatory genes in medicated schizophrenia and bipolar patients[J]. Scand J Immunol, 2017, 86(6):479-485.
[11] Boerrigter D, Weickert T W, Lenroot R, et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder[J]. J Neuroinflammation, 2017, 14(1):188-232.
[12] Goldsmith D R, Haroon E, Miller A H, et al. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia[J]. Schizophr Res, 2018,199:281-284.
[13] Boin F, Zanardini R, Pioli R, et al. Association between-G308A tumor necrosis factor alpha gene polymorphism and schizophrenia[J]. Mol Psychiatry, 2001, 6(1):79-82.
[14] Stroubini T, Perrea D, Perelas A, et al. Effect of sibutramine on regional fat pads and leptin levels in rats fed with three isocaloric diets[J]. Eur Cytokine Netw, 2008, 19(3):149-155.
[15] Fang X, Zhang Y, Fan W, et al. Interleukin-17 alteration in first-episode psychosis:a Meta-analysis[J]. Mol Neuropsychiatry,2018,3(3):135-140.
[16] Borovcanin M, Jovanovic I, Dejanovic S D, et al. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia[J]. Psychoneuroendocrinology, 2015, 56:143-147.
[17] Nora B, Mariam H, Jawad F, et al. Inflammation and elevation of interleukin-12p40 in patients with schizophrenia[J]. Front Mol Neurosci, 2016, 9:16.
[18] Laan W, Grobbee D E, Selten J D, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders:results from a randomized, double-blind, placebo-controlled trial[J]. J Clin Psychiatry, 2010, 71(5):520-527.
[19] Kelly D L, Sullivan K M, McEvoy J P, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms[J]. J Clin Psychopharmacol, 2015, 35(4):374-381.
[20] Weiser M, Levi L, Burshtein S, et al. The effect of minocycline on symptoms in schizophrenia:results from a randomized controlled trial[J]. Schizophr Res, 2018, pii:90920-9964(18)30625-X.
[21] 徐园园, 贾竑晓.精神分裂症临床分期模型的研究进展[J].首都医科大学学报,2018,39(2):213-216.